The deputy director of the Masonic Cancer Center discussed trends of presentations from ESMO 2022.
The patient is expected to qualify for analytical treatment interruption of background anti-retroviral therapy.
Review top news and interview highlights from the week ending September 23, 2022.
The FDA previously lifted its clinical hold of the AFFINE study in May 2022.
The company previously presented positive preclinical data at the 2021 ASGCT meeting.